4586 Medrx Co.,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4586

TSE Growth

Medrx Co.,Ltd.

JPY

-3

(-3.61%)

Dec 23, 3:30 pm JST

0.51

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2020	115	-1,130	-1,152	-1,114	-68.6	0	Feb 10, 2021	J-GAAP
Dec, 2021	8	-1,061	-1,066	-1,059	-49.6	0	Feb 10, 2022	J-GAAP
Dec, 2022	59	-1,098	-1,112	-1,111	-43.8	0	Feb 10, 2023	J-GAAP
Dec, 2023	29	-933	-930	-932	-26.8	0	Feb 9, 2024	J-GAAP
Dec, 2024 Guidance	259	-919	-868	-846	-17.9	0	Aug 9, 2024	J-GAAP
YoY	+793.1%	+1.5%	+6.7%	+9.2%	+33.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2019	Feb 8, 2019	1,009	-650	-656	-643	0	J-GAAP
	May 29, 2019	1,009	-949	-955	-943	0	J-GAAP
	Sep 25, 2019	172	-1,866	-1,871	-1,856	0	J-GAAP
Results	Feb 7, 2020	169	-1,627	-1,633	-1,616	0	J-GAAP
Dec, 2020	Feb 7, 2020	Available in future release
	Apr 16, 2020
	Dec 28, 2020
Results	Feb 10, 2021
Dec, 2021	Feb 10, 2021
	May 18, 2021
	Nov 12, 2021
	Nov 19, 2021
	Dec 27, 2021
Results	Feb 10, 2022
Dec, 2022	Feb 10, 2022
	Nov 11, 2022
	Dec 27, 2022
Results	Feb 10, 2023
Dec, 2023	Feb 10, 2023
	Sep 15, 2023
	Sep 29, 2023
Results	Feb 9, 2024
Dec, 2024	Feb 9, 2024	200	-1,425	-1,384	-1,386	0	J-GAAP
	Apr 24, 2024	442	-1,183	-1,142	-1,144	0	J-GAAP
	Jul 12, 2024	244	-1,298	-1,257	-1,259	0	J-GAAP
	Aug 9, 2024	259	-919	-868	-846	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2007	278	－	Available in future release
Dec, 2008	124	-55.4
Dec, 2009	547	+341.1
Dec, 2010	291	-46.8
Dec, 2011	741	+154.6
Dec, 2012	87	-88.3
Dec, 2013	68	-21.8
Dec, 2014	26	-61.8
Dec, 2015	37	+42.3
Dec, 2016	22	-40.5
Dec, 2017	198	+800.0
Dec, 2018	8	-96.0
Dec, 2019	169	+2,012.5
Dec, 2020	115	-32.0
Dec, 2021	8	-93.0
Dec, 2022	59	+637.5
Dec, 2023	29	-50.8
Dec, 2024 Guidance	259	+793.1	-919	+1.5	-868	+6.7	-17.9	+33.2

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2022	59	-1,098	-1,861	-73.02	-63.38	0.03	-43.8
Dec, 2023	29	-933	-3,217	-62.01	-54.03	0.02	-26.8
Dec, 2024 Guidance	259	-919	-355	-32.92	-31.19	0.10	-17.9

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	741	-434	-147	-166	-26.8
Fiscal Year	Dec, 2011	Dec, 2011	Dec, 2009	Dec, 2009	Dec, 2023

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2021	1	-590	-591	-586	-27.5	0	Feb 10, 2022	J-GAAP
Jul - Dec, 2022	50	-724	-730	-730	-28.8	0	Feb 10, 2023	J-GAAP
Jul - Dec, 2023	23	-455	-450	-451	-13.0	0	Feb 9, 2024	J-GAAP
Jul - Dec, 2024 Guidance	28	-784	-784	-785	-16.6	0	Aug 9, 2024	J-GAAP
YoY	+21.7%	-72.3%	-74.2%	-74.1%	-27.7%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2021	-1,061	-925	-923	-2	815	1,703	80.79	J-GAAP
Dec, 2022	-1,098	-1,074	-1,073	-1	356	994	71.10	J-GAAP
Dec, 2023	-933	-913	-913	0	1,639	1,720	83.82	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2022	9	-621	-636	-635	-25.8	ー	Nov 11, 2022	J-GAAP
Jan - Sep, 2023	29	-670	-668	-671	-20.0	ー	Nov 10, 2023	J-GAAP
Jan - Sep, 2024	255	-379	-343	-320	-7.6	ー	Nov 8, 2024	J-GAAP
YoY	+779.3%	+43.4%	+48.7%	+52.3%	+62.0%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	50	-477	-476	-476	-18.8	-954.0	Feb 10, 2023	J-GAAP
Jan - Mar, 2023	6	-294	-289	-290	-9.6	-4,900.0	May 12, 2023	J-GAAP
Apr - Jun, 2023	0	-184	-191	-191	-5.9	-Inf	Aug 10, 2023	J-GAAP
Jul - Sep, 2023	23	-192	-188	-190	-5.7	-834.8	Nov 10, 2023	J-GAAP
Oct - Dec, 2023	0	-263	-262	-261	-7.5	-Inf	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	0	-176	-127	-128	-3.3	-Inf	May 10, 2024	J-GAAP
Apr - Jun, 2024	231	41	43	67	1.7	17.7	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	24	-244	-259	-259	-6.2	-1,016.7	Nov 8, 2024	J-GAAP
YoY	+4.3%	-27.1%	-37.8%	-36.3%	-8.7%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	1	－	Available in future release
Jan - Mar, 2020	0	-100.0
Apr - Jun, 2020	15	+50.0
Jul - Sep, 2020	0	-100.0
Oct - Dec, 2020	100	+9,900.0
Jan - Mar, 2021	7	－
Apr - Jun, 2021	0	-100.0
Jul - Sep, 2021	1	－
Oct - Dec, 2021	0	-100.0
Jan - Mar, 2022	1	-85.7
Apr - Jun, 2022	8	－
Jul - Sep, 2022	0	-100.0
Oct - Dec, 2022	50	－
Jan - Mar, 2023	6	+500.0
Apr - Jun, 2023	0	-100.0
Jul - Sep, 2023	23	－
Oct - Dec, 2023	0	-100.0
Jan - Mar, 2024	0	-100.0
Apr - Jun, 2024	231	－
Jul - Sep, 2024	24	+4.3	-244	-27.1	-259	-37.8	-6.2	-8.8

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	231	41	43	67	1.7
Fiscal Year	Jun, 2024	Jun, 2024	Jun, 2024	Jun, 2024	Jun, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2021	77.09	89.9	2,108	1,895	-13,279	ー	Feb 10, 2022	J-GAAP
Dec, 2022	40.71	82.1	1,398	1,148	-2,150	ー	Feb 10, 2023	J-GAAP
Dec, 2023	48.44	90.5	2,052	1,858	-915	ー	Feb 9, 2024	J-GAAP
Jan - Sep, 2024	ー	94.8	2,712	2,570	-300	ー	Nov 8, 2024	J-GAAP

Medrx Co.,Ltd.(4586) Financial Results